Ultime notizie per Moleculin Biotech (NASDAQ:MBRX) Azioni

Moleculin Biotech

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Moleculin Biotech Inc

<p>Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.01) by 655.56 percent.  The company reported quarterly sales of $73.97 million which beat the analyst consensus estimate of $71.83 million by 2.97 percent.  This is a 17.25 percent increase over sales of $63.08 million the same period last year.</p>


Earnings

Earnings Beats

News

KRUS

Kura Sushi USA Q3 Adj. EPS $0.05 Beats $(0.01) Estimate, Sales $73.97M Beat $71.83M Estimate

<p><i>- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies -</i></p>
<p><i>- SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA -</i></p>
<p><i>- Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 -</i></p>
<p><i>- Expands Solid's clinical pipeline to include first cardiac indication with urgent unmet medical need -</i></p>


Biotech

General

SLDB

Solid Biosciences Receives FDA IND And Health Canada CTA Approval For First-In-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia

Earnings Misses

Penguin Solutions, Inc. - Ordinary Shares

PENG

Penguin Solutions Q3 Adj. EPS $0.47 Beats $0.33 Estimate, Sales $324.25M Miss $328.81M Estimate

<p>Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.01) by 655.56 percent.  The company reported quarterly sales of $73.965 million which beat the analyst consensus estimate of $71.832 million by 2.97 percent.  This is a 17.25 percent increase over sales of $63.082 million the same period last year.</p>


Kura Sushi USA Q3 Adj. EPS $0.05 Beats $(0.01) Estimate, Sales $73.965M Beat $71.832M Estimate

<p>The Department of Energy (DOE) under President<strong> Donald Trump</strong> released a report warning that the planned shutdown of existing power plants, combined with delays in bringing new energy sources online, could result in a significant increase in blackouts by the <a href="https://www.benzinga.com/trading-ideas/small-cap-analysis/25/07/46299343/oklo-nuscale-hims-defy-trump-tariffs-and-power-the-russell-2000-toward-new-highs">end of the decade.</a></p>
<h3 class="wp-block-heading"><strong>Key Findings from the DOE Report:</strong></h3>
<p>The DOE's report found that approximately 104 gigawatts (GW) of current power generation capacity are set to be retired by 2030.&nbsp;</p>
<p>If these facilities are not replaced promptly, the number of hours Americans experience power outages each year could jump from the current single digits to more than 800 hours without power each year.</p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/markets/tech/25/07/46298744/solar-stocks-sink-trump-slashes-green-tax-breaks?utm_source=articleShare"><strong>Solar Stocks Sink: Trump Slashes Green Tax Breaks</strong></a><strong>&nbsp;</strong></p>
<p>While 209 GW of new capacity is scheduled to come online by 2030, only 22 GW of that will be from reliable, always-available (baseload) sources. The report also notes that even if no retirements occurred, the risk of outages in some regions could still triple.</p>
<p>Secretary of Energy <strong>Chris Wright </strong><a href="https://www.foxbusiness.com/economy/trumps-energy-department-warns-americans-could-face-800-hours-blackouts-2030">told</a> Fox Business that the administration is focused on increasing energy supply from all affordable, reliable and secure sources to meet rising demand and support the country's competitiveness in AI and manufacturing.</p>
<p>&#8220;In the coming years, America's reindustrialization and the AI race will require a significantly larger supply of around-the-clock, reliable, and uninterrupted power,&#8221; Wright said.&nbsp;</p>
<p>&#8220;President Trump's administration is committed to advancing a strategy of energy addition, and supporting all forms of energy that are affordable, reliable, and secure,&#8221; he added. &#8220;If we are going to keep the lights on, win the AI race, and keep electricity prices from skyrocketing, the United States must unleash American energy.&#8221;</p>
<h3 class="wp-block-heading"><strong>Nuclear Alternative:&nbsp;</strong></h3>
<p>Nuclear plants provide continuous, stable electricity, regardless of weather or time of day, unlike solar and wind energy. Nuclear energy could help to mitigate potential energy shortages and is viewed favorably by the Trump administration.</p>
<p>In fact, President Trump signed a <a href="https://www.benzinga.com/news/mid-cap/25/05/45587750/uranium-stocks-surge-trumps-nuclear-push-sparks-double-digit-gains">series of executive orders</a> at the end of May aimed at revitalizing the nuclear energy sector.&nbsp;</p>
<p>Trump invoked the Defense Production Act to declare a national emergency regarding the U.S. reliance on foreign uranium supplies and directed federal agencies to accelerate nuclear project development and remove regulatory barriers. </p>
<p>As federal support shifts toward nuclear technologies, investors may want to monitor the sector.&nbsp;</p>
<p>Some companies that could benefit include<strong> Oklo, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), <strong>NuScale Power Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>), <strong>Nano Nuclear Energy Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) and <strong>Constellation Energy Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>).&nbsp;</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46284237/sofi-ready-to-capture-the-opportunity-as-trumps-big-beautiful-plan-restricts-federal-student-loans?utm_source=articleShare"><strong>SoFi Ready To &#8216;Capture The Opportunity&#8217; As Trump&#8217;s &#8216;Big, Beautiful&#8217; Plan Restricts Federal Student Loans</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Mid Cap

Politics

Movers

Tech

Trading Ideas

OKLO

Get Ready For 800 Hours Of Blackouts, Trump's DOE Warns

<p>Saratoga Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) reported quarterly earnings of $0.66 per share which missed the analyst consensus estimate of $0.93 by 28.8 percent. This is a 37.14 percent decrease over earnings of $1.05 per share from the same period last year.  The company reported quarterly sales of $32.32 million which beat the analyst consensus estimate of $32.29 million by 0.08 percent.  This is a 16.44 percent decrease over sales of $38.68 million the same period last year.</p>


Saratoga Investment Q1 Adj. EPS $0.66 Misses $0.93 Estimate, Sales $32.32M Beat $32.29M Estimate

<p>Aehr Test Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 101.19 percent decrease over earnings of $0.84 per share from the same period last year.  The company reported quarterly sales of $14.089 million which missed the analyst consensus estimate of $14.823 million by 4.95 percent.  This is a 15.13 percent decrease over sales of $16.600 million the same period last year.</p>


AEHR

Aehr Test Systems Q4 Adj. EPS $(0.01), Inline, Sales $14.089M Miss $14.823M Estimate

POAI

On July 1, Predictive Oncology Entered Equity Purchase Agreement With Ya Ii Pn, Ltd.

WIIM

MBLY

Mobileye Global shares are trading lower after the company announced a 45 million secondary share offering.

<p>BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Wednesday, July 9, 2025 at 8:00 a.m. ET to disclose topline results from the randomized, placebo-controlled portion of the Phase 2 trial evaluating bivamelagon, an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.</p>
<p><strong>Conference Call Information</strong><br /><br />Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, July 9, to discuss these clinical data. Participants may register for the conference call <a href="https://www.globenewswire.com/Tracker?data=PMUHCc_o63ptWycjH6Y7DV9X1bk72WjNQ44dm-8QhwgmGSA24YcTeajqP55OvzeSK494H_JZoC6YnW8aeYNWUDYqpqpV7oQRrF_fQO8RSqY=">here</a>. A webcast of the call will also be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at <a href="https://ir.rhythmtx.com/">https://ir.rhythmtx.com/</a>. The archived webcast will be available on Rhythm Pharmaceuticals' website approximately two hours after the conference call and will be available for at least 30 days following the call.</p>
<p><strong>About the Bivamelagon Phase 2 Trial</strong><br /><br />The Phase 2 trial is a randomized, placebo-controlled, double-blind study to assess the effect of bivamelagon (LB54640) on safety, weight reduction, hunger, and quality of life in patients 12 years of age and older (N=28) with hypothalamic obesity. During the placebo-controlled, randomized portion of the trial, patients took an oral daily dose of either bivamelagon, low (200 mg), middle (400 mg), or high dose (600 mg), or placebo for 14 weeks. The primary endpoint of the study was the change from baseline in body mass index after 14 weeks of treatment, and patients may continue on therapy in the open label extension portion for up to 52 weeks.</p>


RYTM

Rhythm Pharmaceuticals To Reveal Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

<p>SR Bancorp, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRBK#NASDAQ">SRBK</a>), the holding company for Somerset Regal Bank, announced today that the Company has authorized a stock repurchase program for up to 10% of the Company's outstanding shares of common stock (886,137 shares). This is the Company's second stock repurchase program since completing its mutual-to-stock conversion and related stock offering on September 19, 2023.</p>


Buybacks

SRBK

SR Bancorp Announces Company Has Authorized A Stock Repurchase Program For Up To 10%, 886,137 Shares, Of The Company's Outstanding Shares Of Common Stock

<p>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) ("Mobileye") today announced the commencement of an underwritten secondary public offering of 45 million shares of Mobileye's Class A common stock by Intel Overseas Funding Corporation, a wholly owned subsidiary of Intel Corporation (the "Selling Stockholder"). The Selling Stockholder intends to grant the underwriters a 30-day option to purchase up to an additional 6.75 million shares of Mobileye's Class A common stock.</p>
<p>In addition, Mobileye has agreed to purchase from the Selling Stockholder $100 million of Mobileye's Class A common stock at a price per share equal to the per share purchase price to be paid by the underwriters in the offering. The concurrent repurchase was approved by the disinterested directors of Mobileye not affiliated with the Selling Stockholder. The concurrent repurchase is expected to be consummated concurrently with the offering. The offering is not conditioned upon the closing of the concurrent repurchase, but the concurrent repurchase is conditioned upon the closing of the offering.</p>
<p>In addition, the Selling Stockholder has informed Mobileye of its plan to voluntarily convert an additional 50 million shares of Mobileye's outstanding Class B common stock that it holds into 50 million shares of Class A common stock, contingent on the closing of the offering. The Selling Stockholder has further informed Mobileye that it intends to hold such shares of Class A common stock at this time and that the conversion of such shares is being effected solely to increase the number of shares of Class A common stock issued and outstanding. The offering is not conditioned upon the closing of the conversion, but the conversion is conditioned upon the closing of the offering.</p>
<p>Mobileye is not selling any shares of Class A common stock in the offering and will not receive any proceeds from the sale of the shares being offered by the Selling Stockholder.</p>
<p>Goldman Sachs &amp; Co. LLC and BofA Securities, Inc. are acting as joint lead book-running managers for the proposed offering.</p>


Offerings

INTC

Mobileye Announces 45M Share Secondary Offering By Intel Unit, $100M Stock Repurchase, And 50M Class B To Class A Share Conversion

<p>In the latest quarter, 12 analysts provided ratings for Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Insmed, presenting an average target of $109.0, a high estimate of $120.00, and a low estimate of $90.00. This current average has increased by 12.48% from the previous average price target of $96.91. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752004868_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Insmed's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$102.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jason Zemansky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$119.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joseph Schwartz</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Insmed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Insmed's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/INSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Insmed analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Insmed</h2>
<p>Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.</p>
<h3>Key Indicators: Insmed's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Insmed's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>22.94%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-276.42%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Insmed's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-133.45%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-13.41%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Insmed's debt-to-equity ratio surpasses industry norms, standing at <strong>11.53</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

INSM

A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts

<p>6 analysts have shared their evaluations of SouthState (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $114.5, a high estimate of $120.00, and a low estimate of $106.00. Highlighting a 6.34% decrease, the current average has fallen from the previous average price target of $122.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752004860_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive SouthState is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$106.00</td>
<td>-</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Russell Gunther</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$119.00</td>
<td>$119.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to SouthState. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SouthState compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of SouthState's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of SouthState's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SSB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on SouthState analyst ratings.</strong></a></p>
<h2>Discovering SouthState: A Closer Look</h2>
<p>SouthState Corp is a United States-based bank holding company. It provides a wide range of services and products to its customers through a wholly-owned bank subsidiary, South State Bank. The Bank provides retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans through financial centers in Alabama, Florida, Georgia, North Carolina, South Carolina, and Virginia. These services include demand, time and savings deposits, lending and credit card servicing, ATM processing, and wealth management and trust services.</p>
<h3>Key Indicators: SouthState's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> SouthState's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>51.78%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>14.13%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> SouthState's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.23%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.16%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> SouthState's debt-to-equity ratio is below the industry average at <strong>0.09</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


6 Analysts Assess SouthState: What You Need To Know

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Shopify</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SHOP, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 34 uncommon options trades for Shopify.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 32% bullish and 55%, bearish.</p>
<p>Out of all of the special options we uncovered, 12 are puts, for a total amount of $701,550, and 22 are calls, for a total amount of $1,141,907.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $135.0 for Shopify during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Shopify's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Shopify's whale activity within a strike price range from $55.0 to $135.0 in the last 30 days. </p>
<h3>Shopify Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752004858_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$18.75</td>
<td>$18.55</td>
<td>$18.64</td>
<td>$110.00</td>
<td>$186.4K</td>
<td>3.0K</td>
<td align="right">110</td>
</tr>
<tr>
<td>SHOP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$2.15</td>
<td>$2.1</td>
<td>$2.15</td>
<td>$108.00</td>
<td>$124.9K</td>
<td>236</td>
<td align="right">506</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/11/25</td>
<td>$2.35</td>
<td>$2.15</td>
<td>$2.35</td>
<td>$118.00</td>
<td>$117.5K</td>
<td>594</td>
<td align="right">614</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.25</td>
<td>$25.0</td>
<td>$25.25</td>
<td>$100.00</td>
<td>$75.7K</td>
<td>2.7K</td>
<td align="right">51</td>
</tr>
<tr>
<td>SHOP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$11.05</td>
<td>$10.95</td>
<td>$11.05</td>
<td>$105.00</td>
<td>$70.7K</td>
<td>75</td>
<td align="right">67</td>
</tr>
</tbody>
</table>
</p>
<h3>About Shopify</h3>
<p>Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.</p>
<p>After a thorough review of the options trading surrounding Shopify, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Shopify</h3>
<ul>
<li>Trading volume stands at 6,191,583, with SHOP's price up by 0.7%, positioned at $117.48.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
<h3>Expert Opinions on Shopify</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $108.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $91.<br />
&#x2A; An analyst from DA Davidson persists with their Buy rating on Shopify, maintaining a target price of $125. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Shopify options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

SHOP

Looking At Shopify's Recent Unusual Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>D-Wave Quantum</strong>.</p>
<p>Looking at options history for D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) we detected 37 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 59% of the investors opened trades with bullish expectations and 35% with bearish.</p>
<p>From the overall spotted trades, 9 are puts, for a total amount of $553,573 and 28, calls, for a total amount of $1,772,359.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $35.0 for D-Wave Quantum, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for D-Wave Quantum's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of D-Wave Quantum's whale trades within a strike price range from $10.0 to $35.0 in the last 30 days. </p>
<h3>D-Wave Quantum Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752004851_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$3.55</td>
<td>$3.3</td>
<td>$3.45</td>
<td>$18.00</td>
<td>$365.1K</td>
<td>4.7K</td>
<td>1.1K</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$3.35</td>
<td>$3.3</td>
<td>$3.3</td>
<td>$18.00</td>
<td>$149.8K</td>
<td>4.7K</td>
<td>1.6K</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$7.35</td>
<td>$7.15</td>
<td>$7.15</td>
<td>$10.00</td>
<td>$107.2K</td>
<td>1.9K</td>
<td>374</td>
</tr>
<tr>
<td>QBTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.93</td>
<td>$1.87</td>
<td>$1.87</td>
<td>$11.00</td>
<td>$102.8K</td>
<td>4.0K</td>
<td>1.2K</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.15</td>
<td>$9.6</td>
<td>$9.6</td>
<td>$12.00</td>
<td>$96.0K</td>
<td>2.2K</td>
<td>103</td>
</tr>
</tbody>
</table>
</p>
<h3>About D-Wave Quantum</h3>
<p>D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.</p>
<h3>Where Is D-Wave Quantum Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 33,591,233, the QBTS's price is down by -4.18%, now at $16.06. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 30 days.</li>
</ul>
<h3>What The Experts Say On D-Wave Quantum</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $19.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Roth Capital continues to hold a Buy rating for D-Wave Quantum, targeting a price of $18.<br />
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on D-Wave Quantum, which currently sits at a price target of $20.<br />
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on D-Wave Quantum, which currently sits at a price target of $20.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $20.<br />
&#x2A; An analyst from B. Riley Securities has decided to maintain their Buy rating on D-Wave Quantum, which currently sits at a price target of $20. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for D-Wave Quantum, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


QBTS

D-Wave Quantum Options Trading: A Deep Dive into Market Sentiment

<p>Synovus Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Synovus Financial, revealing an average target of $55.75, a high estimate of $67.00, and a low estimate of $46.00. A decline of 3.04% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752004853_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Synovus Financial by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$56.00</td>
<td>-</td>
</tr>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Russell Gunther</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Synovus Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Synovus Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Synovus Financial's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Synovus Financial's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SNV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Synovus Financial analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Synovus Financial</h2>
<p>Synovus Financial Corp provides commercial and consumer banking in addition to a full suite of specialized products &amp; services such as private banking, treasury management, wealth management, mortgage services, premium finance, asset-based lending, structured lending, capital markets, &amp; international banking to clients through the wholly-owned subsidiary bank, Synovus Bank, and other offices in Alabama, Florida, Georgia, South Carolina, and Tennessee. It has four segments Wholesale Banking, Community Banking, Consumer Banking, and Financial Management Services, out of which the majority is from the Wholesale banking segment.</p>
<h3>Breaking Down Synovus Financial's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Synovus Financial's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>5.75%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>32.3%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Synovus Financial's ROE excels beyond industry benchmarks, reaching <strong>3.84%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Synovus Financial's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.3%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Synovus Financial's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.43</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Synovus Financial Stands With Analysts

<p>Financial giants have made a conspicuous bearish move on Intuit. Our analysis of options history for Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 30% of traders were bullish, while 61% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $204,150, and 11 were calls, valued at $444,446.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $1000.0 for Intuit over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Intuit stands at 106.38, with a total volume reaching 127.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Intuit, situated within the strike price corridor from $300.0 to $1000.0, throughout the last 30 days.</p>
<h3>Intuit Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752004846_0_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$66.0</td>
<td>$65.1</td>
<td>$66.0</td>
<td>$800.00</td>
<td>$105.6K</td>
<td align="right">17</td>
<td align="right">31</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$65.7</td>
<td>$64.5</td>
<td>$65.7</td>
<td>$800.00</td>
<td>$98.5K</td>
<td align="right">17</td>
<td align="right">15</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$12.8</td>
<td>$12.2</td>
<td>$12.2</td>
<td>$860.00</td>
<td>$54.7K</td>
<td align="right">399</td>
<td align="right">45</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$498.0</td>
<td>$488.0</td>
<td>$494.24</td>
<td>$300.00</td>
<td>$49.4K</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$487.2</td>
<td>$479.0</td>
<td>$484.79</td>
<td>$310.00</td>
<td>$48.4K</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuit</h3>
<p>Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small business accounting and do-it-yourself tax filing in the US.</p>
<h3>Where Is Intuit Standing Right Now?</h3>
<ul>
<li>With a volume of 705,213, the price of INTU is down -0.18% at $782.21. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 44 days.</li>
</ul>
<h3>Expert Opinions on Intuit</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $890.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Intuit, maintaining a target price of $900.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Intuit with a target price of $880. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Intuit, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


INTU

Smart Money Is Betting Big In INTU Options

<p><a href="https://ppubs.uspto.gov/api/pdf/downloadPdf/12350242?requestToken=eyJzdWIiOiJlMmEyMTIwZi01YWZmLTQ5NGMtYjFkYi1lZTVmMmQ3MzM4NDgiLCJ2ZXIiOiJkNTc5MmM2MC00MzhmLTRkOGItODRjNy1iZWM5NjU2YjRjZTQiLCJleHAiOjB9" title="https://ppubs.uspto.gov/api/pdf/downloadPdf/12350242?requestToken=eyJzdWIiOiJlMmEyMTIwZi01YWZmLTQ5NGMtYjFkYi1lZTVmMmQ3MzM4NDgiLCJ2ZXIiOiJkNTc5MmM2MC00MzhmLTRkOGItODRjNy1iZWM5NjU2YjRjZTQiLCJleHAiOjB9">https://ppubs.uspto.gov/api/pdf/downloadPdf/12350242?requestToken=eyJzdWIiOiJlMmEyMTIwZi01YWZmLTQ5NGMtYjFkYi1lZTVmMmQ3MzM4NDgiLCJ2ZXIiOiJkNTc5MmM2MC00MzhmLTRkOGItODRjNy1iZWM5NjU2YjRjZTQiLCJleHAiOjB9</a></p>


CMND

Clearmind Medicine Granted U.S. Patent #12,350,242 For "BINGE BEHAVIOR REGULATORS"

<p><strong>ICICI Bank's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBN#NYSE">IBN</a>) short percent of float has fallen 10.45% since its last report. The company recently reported that it has <strong>20.02 million shares sold short</strong>, which is 1.2% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 5.65 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>ICICI Bank Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752004846_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for ICICI Bank has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing ICICI Bank's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, ICICI Bank's peer group average for short interest as a percentage of float is 0.92%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

How Is The Market Feeling About ICICI Bank?

Press Releases

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Announces $5.9 Million Public Offering

MBRX

AIM ImmunoTech

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

180 Life Sciences

Bone Biologics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Unity Biotechnology

VivoSim Labs

Xenetic Biosciences

HC Wainwright & Co.

Maxim Group

Roth MKM

Oppenheimer

Moleculin Biotech shares are trading higher after the company announced it has been granted European Patent Number EP3990041 titled "METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN (FOR THE TREATMENT OF CANCER).

Comments

Moleculin Biotech

Notizie

Ultime notizie per Moleculin Biotech (NASDAQ:MBRX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO